212127-81-6

Basic information

• Product Name: 3,6-dihydropyran-5-boronic ester
• Synonyms: 3,6-dihydropyran-5-boronic ester;2-(5,6-Dihydro-2H-pyran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;(5,6-DIHYDRO-2H-PYRAN-3-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 212127-81-6
• Molecular Formula: C₁₁H₁₉BO₃
• Molecular Weight: 210.08
• Product Categories: Organic boronic acid
• Mol File: 212127-81-6.mol

Chemical Properties

• Boiling Point: 238.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.01±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 3,6-dihydropyran-5-boronic ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dihydropyran-5-boronic ester(212127-81-6)
• EPA Substance Registry System: 3,6-dihydropyran-5-boronic ester(212127-81-6)

Safety Data

• Hazardous Substances Data: 212127-81-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3,6-dihydropyran-5-boronic ester is used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and materials. Its unique chemical properties allow it to be a key component in the creation of a wide range of compounds.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
3,6-dihydropyran-5-boronic ester is used as a reagent in Suzuki-Miyaura cross-coupling reactions for the formation of carbon-carbon bonds. This reaction is a powerful tool in organic chemistry, enabling the formation of new compounds with specific structural features.
Used in Drug Development:
3,6-dihydropyran-5-boronic ester has potential applications in the development of new drug candidates. Its ability to form carbon-carbon bonds and its compatibility with various chemical reactions make it a valuable component in the design and synthesis of novel pharmaceuticals.
Used as a Ligand in Transition Metal Catalysis:
3,6-dihydropyran-5-boronic ester is used as a ligand in transition metal catalysis. Its presence can enhance the catalytic activity of transition metal complexes, facilitating various chemical transformations and improving the efficiency of catalytic processes.
Handling and Storage:
Due to its sensitivity to air and moisture, 3,6-dihydropyran-5-boronic ester is typically handled and stored under an inert atmosphere to maintain its stability and reactivity. This precaution ensures that the compound remains effective for its intended applications in various industries.

Upstream product

• 212127-72-5 2-[3-(but-3-en-1-yloxy)prop-1-en-2-yl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1227068-80-5 5,6-dihydro-2H-pyran-3-yl trifluoromethanesulfonate 
• 73183-34-3 bis(pinacol)diborane 
• 23462-75-1 5,6-dihydro-2H-pyran-3(4H)-one 
• 93199-28-1 4-(prop-2-yn-1-yloxy)but-1-ene 

Relevant articles and documents

Multigram Synthesis of Heterabicyclo[n.1.0]alkan-1-yl Trifluoroborates

An approach to the synthesis of oxa- and azabicyclo[n.1.0]alkan-1-yl trifluoroborates on a multigram scale was developed. Two synthetic strategies were evaluated: the first based on the lithiation–borylation of the corresponding 2-bromoallyl derivatives, and the other relying on regioselective hydroboration of the appropriate hetera-substituted enynes. The second method appeared to be more efficient in terms of scalability and substrate scope. Further steps included ring closing-metathesis, mild palladium-catalyzed cyclopropanation with diazomethane, and reaction with KHF2 and furnished the title compounds in up to 50 g scale in a single run (10–41 % overall yield, 4–5 steps).

Pyrrolopyrazole derivative and preparation method thereof, and applications of pyrrolopyrazole derivative in medicine

The present invention relates to a pyrrolopyrazole derivative and a preparation method thereof, and applications of the pyrrolopyrazole derivative in medicine, particularly to a class of new pyrrolopyrazole derivatives represented by a general formula (I), and a preparation method thereof, and uses of the pyrrolopyrazole derivatives or pharmaceutical compositions containing the pyrrolopyrazole derivatives as treating agents, particularly as gastric acid secretion inhibitors and potassium ion competitive acid blockers (P-CABs) in biomedicine, wherein various substituents (R, R and R) and the groups (X, Y and Z) in the formula (I) are defined in the specification.

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties

Two 1-(4-aryl-5-alkyl-pyridin-2-yl)-3-methylurea glucokinase activators were identified with robust in vivo efficacy. These two compounds possessed higher solubilities than the previously identified triaryl compounds (i.e., AM-2394). Structure-activity re

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.